



ThermoFisher
SCIENTIFIC  **19th Workshop** 
of the Study Group
„Immunobiology of Viral Infections“
of the Society for Virology (GfV)
September 30, 2020
Virtual Format!

Supported by



ThermoFisher
SCIENTIFIC

eppendorf

Organisation:

Hana-Mari Baldauf (Max von Pettenkofer Institut, München)
Asisa Volz (Tierärztliche Hochschule, Hannover)

Session I **Innate Immunity to Viral Infections**

Session II **Adaptive Immunity to Viral Infections**

Wednesday, September 30, 2020

09:00 - 09:15 *Opening Remarks*

Keynote lecture

09:15 - 10:00 **Alain Rico, Senior Manager Market Development EMEA, ThermoFisher**

How Thermo Fisher Scientific is responding to COVID-19 crisis

Session I Innate Immunity to Viral Infections

10:00 - 10:15 **Fabian Kriesel, Max von Pettenkofer, LMU Munich**

Evaluation of the antiviral activity of SERINC5 on MLV infectivity

10:15 - 10:30 **Lu Zhang, Max von Pettenkofer, LMU Munich**

Initial characterization of RELIK Tat to study ancient antiviral mechanisms

10:30 - 10:45 **Nicola Frericks, Twincore, Hannover**

Determinants of hepatitis C virus (HCV) resistance to interferon (IFN)

10:45 - 11:00 **Caterina Prelli Bozzo, Institute for Molecular Virology, Ulm University**

IFITM proteins promote SARS-CoV-2 infection in human lung cells

Keynote lecture

11:00 - 11:45 **Florian Klein, Institute of Virology, University Hospital Köln**

Antibody-mediated Neutralization of SARS-CoV-2

11:45 - 12:00 **Bengisu Akbil, Institute of Virology, Charité Berlin**

Characterization of the role of LGALS3BP (90K) in the context of HIV-1 and SARS-CoV-2 infection

12:00 - 12:15 **Zhenfeng Zhang, Department of Infectious Diseases, University Hospital Heidelberg**

IFN response blocks cell-division-mediated HDV spread and suppresses HDV persistence synergistically with inhibitors targeting extracellular spread

12:15 - 13:15 *Break*

Session II Adaptive Immunity to Viral Infections

- 13:15 - 13:30 **Manivel Lodha**, Institute for Virology and Immunobiology, Julius-Maximilian University Würzburg
Deciphering the antigenic potential of murine cytomegalovirus sORF-derived peptides
- 13:30 - 13:45 **Sara Hamdan**, Institute of Virology, Johannes Gutenberg-University Mainz
Immunomodulation of cytomegalovirus by regulatory T cells
- 13:45 - 14:00 **Matthias Herrmann**, Institute of Virology, University Hospital Freiburg
Shedding of membrane-anchored human cytomegalovirus encoded vFcyR gp34 from infected cells – a potential key immune-evasion mechanism by a member of the HCMV RL11 gene family?

Keynote lecture

- 14:00 - 14:45 **Marylyn Addo, Section Infectious Diseases, UKE Hamburg**
Vaccines against emerging infections
- 14:45 - 15:15 *Break*
- 15:15 - 15:30 **Avinash Kumar**, Department of Pharmaceutical Chemistry MAHE, Manipal, India
Identification of T-cell epitope-based vaccine against spike protein of SARS-CoV-2 employing machine learning empowered in silico tools
- 15:30 - 15:45 **Anna Henning**, Institute of Virology, University Hospital Freiburg
A human cytomegalovirus (HCMV)-encoded glyco-protein, RL11/gp34, antagonizes CRP-activation of FcyRI/CD64
- 15:45 - 16:00 **Katja Hoffmann**, Institute of Virology, University Hospital Freiburg
Protection of human cytomegalovirus (HCMV)-infected cells by virion-derived 'incoming' vFcyRs at initial stages of replication
- 16:00 - 16:15 **Melina Winkler**, Twincore, Hannover
Mechanisms and determinants of HCV species tropism
- 16:15 - 16:30 **Sandra Stelzer**, Robert Koch-Institute, Berlin
Design and immunogenicity evaluation of Adeno-associated virus (AAV) – vectors containing SARS-CoV-2 receptor-binding domain (S-RBD)

Keynote lecture

- 16:30 - 17:15 **Sarah Schmidt, Hookipa Pharma, Wien**
Supercharging Immunotherapy: Arenavirus-based Vectors for Infectious Diseases and Active Cancer Immunotherapy
- 17:15 - 17:30 *Closing Remarks*